New pretreatment of blood tumor targeted therapy? New Sharp Bio has received $110 million to push hematopoietic stem cells into clinical medicine.

Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! This article is originally created by medical Mac, welcome to share, and reprint must be authorized. July 12, 2020 / emedclub news / - - recently, a new biological company named VOR biopharma announced that it has completed the b-round financing of US $110 million, in order to promote the company's main candidate product vor33 into clinical trials, deepen its product portfolio, and accelerate the verification of other targets of its scientific platform.this round of financing is led by RA capital management.it is worth mentioning that VOR's core technology is based on the research of Siddhartha Mukherjee, an opinion leader in the field of cancer, and the author of "the king of diseases: cancer".VOR said that its core technology, engineered hematopoietic stem cells (ehsc), has a strong potential to expand the scope of application of targeted therapy for blood tumors and avoid therapeutic adverse events caused by the killing of therapeutic molecules on healthy cells.release the potential of targeted therapy. At present, targeted therapy such as car-t cell therapy, antibody drugs and so on, has achieved certain results in cancer treatment, but the development and selection of targets is still a major factor limiting its development.usually, the proteins specifically expressed on tumor cells will be selected as targets in targeted therapy. However, it is worrying that these proteins will also be expressed at low levels in some normal tissues, which is one of the main factors causing therapeutic related adverse events.using its core technology platform, VOR aims to solve such obstacles in targeted therapy for hematological tumors.the core technology platform of VOR is to engineer hematopoietic stem cells (HSCs) through gene editing, so that they lose specific proteins with redundant biological functions (meaning that the loss of such proteins will not cause damage, nor affect the normal function of cells).this makes the engineered hematopoietic stem cells lose the target protein and are no longer killed by targeted therapeutic molecules. At the same time, targeted therapy can kill tumor cells better.} image source: vorbiopharma in short, VOR is the main candidate product developed for acute myeloid leukemia (AML). For example, AML tumor cells express CD33 at a high level, but healthy human blood cells also express CD33, which makes it difficult for CD33 targeted therapy to treat AML.vor33 is a genetically engineered hematopoietic stem cell, which lacks the expression of CD33.then vor33 is infused into patients, vor33 will differentiate into blood cells that do not express CD33, participate in the normal operation of human blood system, and reduce the number of healthy cells expressing CD33.previous studies have shown that individuals can live a healthy life even if they do not express CD33.at this time, if the patient is treated with CD33 targeted therapy, the CD33 targeted therapeutic molecules will not attack the blood cells derived from vor33, but will only attack the target cells with CD33.that is, "exposing tumor cells and hiding healthy cells".this avoids the killing effect of CD33 targeted therapy on related healthy cells, and expands the therapeutic scope and effectiveness of CD33 targeted therapy, which may expand the clinical benefits of acute myeloid leukemia.the company publishes more preclinical data in the journal PNAS. } image source: PNAs at the same time, the funds obtained this time will be used to promote the clinical trial of vor33, which is expected to enter the clinical stage next year. the engineered hematopoietic stem cells (ehsc) of VOR company first collected HSCs from matched healthy donors, and then the HSCs were genetically engineered to knock out the gene expressing the target protein, and then they were infused into patients. } VOR company's candidate product schematic diagram (photo source: vorbiopharma) focuses on four popular biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy. The 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Year cultural center, China, on July 19-21, 2020! Click the picture above to view the agenda of the conference